Compassionate mesenchymal stem cell treatment in a severe COVID-19 patient: a case report

COVID-19 presentations range from cold-like symptoms to severe symptoms with the development of acute respiratory distress syndrome (ARDS). We report on a severe COVID-19 patient who was mechanically ventilated and who developed ARDS and bacterial infection. Because of rapid clinical deterioration and the exhaustion of other treatment options, the family and attending physicians requested a compassionate use of adult allogeneic bone marrow-derived mesenchymal stem cells (MSC) in addition to commonly used immunosuppressive, antiviral, and supportive therapy. The clinical course is discussed thoroughly, with a special emphasis on the safety and effect of MSC therapy. Compassionate MSC treatment, given in three rounds, affected ARDS regression. The patient was discharged from the intensive care unit after 31 days and from hospital after 49 days in a good general condition. MSC treatment was not associated with any side effects and was well tolerated in a three-week period; therefore, it should be studied in larger trials and considered for compassionate use.
We report on a case of severe COVID-19 in a 50-year-old male patient who was treated with an infusion of parenteral mesenchymal stem cells (MSC) (Table 1). The pathophysiologic mechanism of COVID-19 is not yet fully understood, but some patients experience a strong immune response, with a release of pro-inflammatory cytokines and chemokines causing a “cytokine storm.” These patients present with a severe clinical course, acute respiratory distress syndrome (ARDS), and require mechanical respiratory support (1,2). Studies investigating MSC in COVID-19 treatment have shown good results in reducing the serum levels of pro-inflammatory cytokines and chemokines, which are the main driver of ARDS in these patients (3).

CASE REPORT

The patient first presented to the emergency department of University Hospital Split, Križine, after five days of home isolation and COVID-19 treatment. He had a fever of up to 38.5 °C, myalgia, and diarrhea. As a medical doctor in the same hospital, the patient had been in contact with COVID-19 patients and coworkers. Medical history was unremarkable and no chronic medical conditions were reported. Before admission, the patient was treated for five days with antipyretics, which resolved fever, and azithromycin. Upon the first hospital presentation, he was eupneic, with blood oxygen saturation (SaO₂) of 97%. The laboratory results indicated a barely increased C-reactive protein (CRP) of 11.3 mg/L. A chest x-ray showed bilateral basal and perihilar opacifications. The patient was released for home treatment, with prescribed 32 mg methylprednisolone for seven days in a de-escalating pattern.

Four days later, the patient visited the emergency department again, with worsening symptoms (fever over 39 °C and dry cough). In between the hospital visits, methylprednisolone dose was escalated to 64 mg and amoxicillin and clavulanic acid were added after finishing azithromycin. SaO₂ upon the second presentation was 94%. Laboratory tests (Table 2) indicated elevated leukocytes (10.9 × 10⁹/L) with neutrophil predominance (90.4%, lymphocytes 5.7%) and mildly elevated CRP of 24.9 mg/L. A native chest CT showed extensive bilateral ground-glass opacities (Figure 1). High-flow oxygen was increased to 45 L/min. On the sixth day of hospitalization, the patient was dyspneic. Laboratory findings suggested an increased inflammatory response, with SaO₂ 87% (Table 2). CT pulmonary angiography showed no signs of pulmonary embolism, but it did show a progression of bilateral consolidations (Figure 1). High-flow oxygen was increased to 45 L/min. On the same day, the patient was examined for severe thrombocytopenia (10 × 10⁹/L) by a hematologist, who diagnosed immunogenic thrombocytopenia, administered intravenous immunoglobulins (400 mg/kg for 5 days), and changed the dose of methylprednisolone to 100 mg.

On the seventh day of hospitalization, the patient was referred to the COVID-19 intensive care unit (ICU), where he was sedated, intubated, and started mechanical ventilation (synchronized intermittent mandatory ventilation f/24min, TV 440 mL; first FiO₂ 100%, then gradually decreased to 80%) in a prone position, which improved blood oxygenation. On the same day, FiO₂ was gradually reduced to 50%. Bronchoscopy, performed the following day, was unremarkable. The D-dimer levels were immeasurably high (>35.2 mg/L) (Table 2). The patient was given a dose of COVID-19 convalescent plasma (CCP). The plasma was obtained in the Croatian Institute of Transfusion Medicine from a healthy donor with a documented history of SARS-CoV-2 infection who had been asymptomatic for ≥28 days and was specified eligible according to standard blood donor criteria. SARS-CoV-2 neutralizing antibodies in CCP were quantified by infective-virus neutralization assay, using a reference calibrated according to the First WHO International Standard for anti-SARS-CoV-2 immunoglobulin (human) (NIBSC code 20/136, NIBSC, Potters Bar, UK), so the titer is expressed in international units per millilitre (IU/mL) (4). The volume of the CCP dose used for therapy was 200 mL, and the titer of neutralizing antibodies was 242 IU/mL.

Since all conventional and recognized therapies had been exhausted, the hospital ethics committee and drug committee approved the use of MSC compassionate treatment upon the request of the attending physicians and after obtaining written consent from the patient’s wife. During the ICU stay, the patient was given three doses of ImmunartaTM (Educell Ltd, Trzin, Slovenia, member of Medical Biobank Swiss Institute SA), allogenic, HLA-incompatible, and non-related bone marrow-derived MSC. The first dose (10⁶ cells/kg) was administered intravenously...
**TABLE 1.** Timeline of the disease and treatment course

| Day of hospitalization | Clinical, radiological, and laboratory findings |
|------------------------|-------------------------------------------------|
| 1st day of the disease | First presented to the emergency department of a regional COVID-19 center after five days of home isolation and COVID-19 treatment.  
Symptoms: fever of up to 38.5 °C, myalgia, and diarrhea.  
Clinical findings: eupneic, blood oxygen saturation (SaO₂) 97%.  
Laboratory results: elevated C-reactive protein (CRP) 11.3 mg/L.  
Chest x-ray: bilateral basal and perihilar opacifications.  
Treatment: released for home treatment with 32 mg methylprednisolone for 7 d in a de-escalating pattern. |
| 1st (4th day of the disease) | Presented with worsening symptoms. Methylprednisolone dose escalated to 64 mg and added amoxicillin and clavulanic acid after finishing azithromycin.  
Symptoms: fever over 39 °C, dry cough.  
Clinical findings: SaO₂ 94%.  
Laboratory results: elevated leukocytes (10.9 × 10^9/L) with neutrophil predominance (90.4%, lymphocytes 5.7%), mildly elevated CRP 24.9.  
Chest computed tomography (CT): extensive bilateral ground-glass opacities.  
Treatment: admission to a specialized COVID-19 ward, remdesivir (200 mg iv), methylprednisolone 240 mg, enoxaparin 0.6 mL, moxifloxacin 400 mg, and supportive antipyretic therapy. |
| 2nd | Oxygen supplementation was started with 2 L/min nasal cannula. |
| 3rd | The condition continued to worsen (SaO₂ 91%). High-flow oxygen therapy (35 L/min) initiated. |
| 6th | Clinical deterioration with dyspnea. SaO₂ 87%.  
Laboratory findings suggested an increased inflammatory response and severe thrombocytopenia (10 × 10^9/L).  
CT pulmonary angiography showed no signs of pulmonary embolism but showed a progression of bilateral consolidations.  
Treatment: high-flow oxygen increased to 45 L/min.  
Hematologist consulted: immunogenic thrombocytopenia. Intravenous immunoglobulins (400 mg/kg), methylprednisolone changed to 100 mg. |
| 7th | Referral to a COVID-19 intensive care unit (ICU). Mechanical ventilation started (synchronized intermittent mandatory ventilation f/24min, TV 440 mL; first FiO₂ 100%, then gradually decreased to 80%). FiO₂ was gradually reduced to 50% the same day. |
| 8th | The patient was given a dose of convalescent plasma. Immeasurably high levels of D-dimers (>35.2 mg/L). |
| 9th | The hospital ethics and drug committees approved mesenchymal stem cells (MSCs) compassionate treatment.  
The first dose of allogenic bone marrow-derived MSCs (10^6 cells/kg) was given. |
| 12th | The second dose of allogenic bone marrow-derived MSCs was given.  
The patient was transferred to a tertiary hospital center for further treatment.  
The therapy was continued, and the patient was mechanically ventilated. |
| 13th | Continued to clinically worsen. SaO₂ below 90%. Later the same day developed subcutaneous emphysema.  
Laboratory results: reduction of inflammatory parameters.  
Bronchoscopy: abundant yellowish secretion, sent for microbiologic evaluation.  
Chest CT: extensive airspace opacifications and pneumomediastinum.  
Low ventilation compliance (tidal volumes below 350 mL) with decreasing SaO₂ levels indicating acute respiratory distress syndrome.  
Microbiologic culture of the bronchial aspirate: methicillin-resistant Staphylococcus aureus and Acinetobacter Baumannii.  
Treatment: recruitment maneuver, high positive end-expiratory pressure (PEEP) (Hamilton-Intellivent ASV) with low driving pressure (below 14 cm H₂O).  
PEEP was continuously reduced in the following days. Antibiotic treatment (colistin 9 million i.u. initially, the next and following days 2 × 4.5 million i.u., fosfomycin 3 × 8 g, and linezolid 2 × 600 mg) |
| 15th | Repeated bronchoscopy showed the same findings.  
Chest x-ray: no reduction in subcutaneous emphysema. |
| 16th | The third dose of allogenic bone marrow-derived MSCs was given.  
Chest x-ray: regression of opacifications.  
Later the same day paroxysmal hypertension >200 mm Hg and tachycardia >140/min.  
Echocardiography: analysis impeded by pneumomediastinum, normal left ventricle morphology, ejection fraction of 50%. |
on the ninth day of hospitalization. MSC doses were prepared from the bone marrow of a young, healthy donor, who agreed to make the donation for allogeneic treatment. The donor was negative for viral markers (HBs Ag, HBc Ab, HCV Ab, HIV 1-2 Ab, TPHA, HBV NAT, HCV NAT, HIV NAT) according to EU legislation, Directive 2004/23/EC of the European Parliament and the Council of the European Union (the body setting the quality and safety standards for donation, procurement, testing, processing, preservation, storage, and distribution of human tissues and cells). The cells were prepared for hospital exemption use in a controlled and verified laboratory in a cleanroom facility in a class A safety cabinet following the guidelines and principles of good manufactured practice. The cultivated cells used in therapy showed morphological characteristics of MSC and expressed CD105, CD73, and CD90, but not CD45 and CD34. The patient’s laboratory parameters were monitored daily, showing a decrease in D-dimer and CRP levels in a three-day period (Table 2).

The second MSC dose was given on the twelfth day of hospitalization. The treatment was continued in the non-COVID ICU, University Hospital Split, Firule, since the patient was no longer considered contagious. The patient experienced paroxysmal hypertension >200 mm Hg and tachycardia >140/min. Echocardiography, although impeded by pneumomediastinum, showed normal left ventricle morphology with an ejection fraction of 50%. On the seventeenth day, the patient was extubated and put on high-flow oxygen (60 L/min), with satisfying peripheral blood oxygen saturation. The clinical condition continued to improve, and oxygen supplementation needs were lowering, with
only nasal cannula being sufficient on the nineteenth day of hospitalization. The patient was also able to verticalize in the course of physical therapy.

On the twentieth day, the patient complained of lower urinary tract pain. Urine samples (bacteriuria) suggested a urinary tract infection. Since blood cultures were positive for gram-negative bacilli, ceftazidime/avibactam (3 × 2.5 g iv) therapy was started.

In the following days, the condition was stable. Leukocytes returned to physiological levels on the twenty-second day of hospitalization. A chest CT performed on the twenty-third day of hospitalization showed a regressive dynamic of air-space opacifications (Figure 1). CRP levels continued to decline and were normal on the thirty-first day of hospitalization, when all antibiotics were discontinued. The patient was able to perform basic physical activities on his own, without the need for oxygen supplementation, and on the thirty-first day of hospitalization was transferred to a physical medicine clinic. The patient remained in the hospital for an additional observation and rehabilitation period, after which he was discharged on the forty-ninth day of hospitalization.

**DISCUSSION**

This case study describes the clinical course of the first Croatian patient treated with MSC for severe COVID-19. The

### Table 2. The patient’s key laboratory findings

| Day of hospitalization | Leukocytes (10⁹/L) | PT | D-dimers (mg/L) | Albumin (g/L) | CRP (mg/L) | Procalcitonin (ng/mL) | Ferritin (ng/mL) | LDH (U/L) |
|------------------------|-------------------|----|----------------|---------------|------------|----------------------|-----------------|-----------|
| 1st day of the disease | 4.50              | /  | 0.39           | 11.3          | /          | /                    | 2270            |           |
| 1st (4th day of the disease) | 10.90              | 1.23 | 0.65          | 39.9          | 24.9       | /                    | /               | 445       |
| 6th                    | 17.30             | 1.01 | 21.9          | 27.0          | 17.0       | 0.08                 | 1535            | 663       |
| 7th                    | 14.40             | 0.78 | >35.2         | 24.4          | 17.0       | 0.07                 | /               | /         |
| 8th                    | 15.30             | 0.94 | >35.2         | 25.7          | 62.0       | /                    | /               | 475       |
| 8th                    | 15.90             | /   | /             | /             | /          | /                    | /               | /         |
| 9th                    | 14.20             | 0.92 | >35.2         | 24.9          | 35.8       | 0.08                 | /               | /         |
| 10th                   | 16.7              | 0.95 | >35.2         | /             | 23.6       | 0.03                 | 850             | /         |
| 11th                   | 17.2              | 1    | 31.98         | 24.4          | 37.6       | 0.16                 | /               | 324       |
| 12th                   | 1.6               | 1.08 | 13.42         | 24.9          | 23.7       | 0.11                 | 1,285           | 292       |
| First round of MSC     |                   |     |               |               |            |                      |                 |           |
| 12th                   | 15.1              | 1.1  | 16.44         | 27.3          | 20.5       | 0.11                 | 1,008           | 305       |
| 13th                   | 14.8              | 1.09 | /             | 30.4          | 17.9       | 0.11                 | /               | 269       |
| 14th                   | 12.9              | 1.21 | /             | 31.8          | 58.9       | 0.14                 | /               | /         |
| 16th                   | 12.5              | 0.97 | /             | /             | 31         | 0.08                 | /               | /         |
| Second round of MSC    |                   |     |               |               |            |                      |                 |           |
| 12th                   | 15.1              | 1.1  | 16.44         | 27.3          | 20.5       | 0.11                 | 1,008           | 305       |
| 13th                   | 14.8              | 1.09 | /             | 30.4          | 17.9       | 0.11                 | /               | 269       |
| 14th                   | 12.9              | 1.21 | /             | 31.8          | 58.9       | 0.14                 | /               | /         |
| 16th                   | 12.5              | 0.97 | /             | /             | 31         | 0.08                 | /               | /         |
| 17th                   | 11.1              | 0.75 | /             | 29.3          | 25.1       | 0.1                  | /               | /         |
| Third round of MSC     |                   |     |               |               |            |                      |                 |           |
| 18th                   | 12                | 1.03 | /             | 31.1          | 28.2       | 0.1                  | /               | /         |
| 19th                   | 17.2              | 1.01 | 7.33          | 34.3          | 25.7       | 0.09                 | 2,154           | 389       |
| 20th                   | 12.5              | 0.94 | /             | 31.5          | 1270       | 0.18                 | /               | /         |
| 21st                   | 13.5              | 0.97 | /             | 33.8          | 899        | 0.15                 | /               | /         |
| 22nd                   | 9.8               | 0.87 | /             | 33.8          | 772        | 0.15                 | /               | /         |
| 23rd                   | 7.9               | /    | 12.5          | /             | 56.0       | 0.12                 | /               | /         |
| 24th                   | 7.5               | 1.06 | /             | /             | 40.1       | 0.15                 | /               | /         |
| 25th                   | 6.4               | 0.94 | /             | 32.3          | 26.2       | 0.11                 | /               | /         |
| 26th                   | 7.4               | 0.92 | /             | 36.9          | 24.6       | 0.08                 | /               | 260       |
| 28th                   | 9.2               | /    | /             | 8.7           | 0.07       | /                    | /               | /         |
| 30th                   | 9.6               | 0.95 | 5.26          | 43.1          | 4.3        | 0.09                 | 837             | 235       |

*Abbreviations: PT – prothrombin time; CRP – C reactive protein; LDH – lactate dehydrogenase; MSC – mesenchymal stem cells; empty row – period of mechanical ventilation.

www.cmj.hr
The patient’s clinical condition progressively worsened since admission and he eventually required mechanical ventilation. The treatment consisted of corticosteroids, immunoglobulins, and convalescent plasma, all of which were indicated due to their anti-inflammatory properties. No Croatian national guidelines on the use of CCP are currently available. In the present case, CCP was used due to its possible immunomodulatory effects, rather than due to its neutralizing antiviral effects (5). This decision was based upon FDA recommendations that the possible benefits of CCP outweigh the risks in critically ill COVID-19 patients (6). Remdesivir was also used, for 5 days.

Since the conventional therapeutic approach was unsuccessful, compassionate use of MSC therapy was initiated, following the Article 83 Regulation EC No 726/2004 of the European Parliament and Council of the European Union. Upon request of the attending physicians in University Hospital Split, Križine, and the patient’s family, MSC were obtained from a young, living donor, and prepared as described previously. After our initial contact with Educell Ltd, all the relevant documentation on ImmunoART™ MSC harvesting, expansion, and delivery methods, as well as the opinion of the Slovenian drug regulating agency, was provided to the ethics committee of University Hospital Split. Croatian Ministry of Health was informed about the planned procedure. Meanwhile, Educell Ltd declared the use of MSC for humanitarian purposes, thereby providing them free of charge. No additional approvals were requested after the transfer to University Hospital Split, Firule, as both hospitals are considered a single administrative unit.

MSC are pluripotent stem cells differentiating into different mesodermic and non-mesodermic lineages. Their secretome consists of immunomodulatory cytokines and chemokines, which were previously shown to modulate endothelial and epithelial permeability, promote endothelial repair, decrease scarring, and act anti-inflammatory (7). Autologous MSC are used in orthopedics and have shown good results in pain reduction and increasing joint mobility, without any observed treatment-specific side effects (8-10).

MSC are immune-privileged cells with a strong immunomodulatory (via IL-10, TGFβ, IDO, PGE2), antimicrobial (via antimicrobial peptide LL-37), and regenerative properties (via VEGF, KGF, EGF) (11,12). Preclinical studies have shown that after iv administration MSC remain “trapped” in the lung during the first passage, so, in the context of ARDS and COVID-19, they accumulate in the target tissue (13). Besides, MSC modulate the immune response via macrophages transition from an inflammatory M1 into an anti-inflammatory M2 phenotype (14,15). In addition, animal models showed the potential of their use for virus-induced pneumonia, ADRS, and lung failure treatment (16). At the moment of writing, clinicaltrial.gov lists 72 registered trials on MSC use in COVID-19 patients (17). Phase-one clinical trials have proven MSC therapy to be well tolerated and safe (11). A recent application of adipose tissue-derived MSC in 13 patients with severe COVID-19 pneumonia on medical ventilation significantly reduced the inflammatory parameters (CRP, IL-6, ferritin, LDH, D-dimer) (18). These findings are in line with those demonstrated in a systematic review and meta-analysis by Qu et al, who found no related serious adverse events after intravenous or intratracheal administration of allogenic MSC of various origin, as well as observed an improved lung function, radiographic findings, and inflammatory biomarkers level (19).

**FIGURE 1.** Chest computed tomography (CT) images (coronal reconstruction) at three time points. (A) Diffuse bilateral areas of ground glass opacities in all lobes at the first day of hospitalization. (B) Mixed airspace and ground glass opacities sparing only the lung apices at the thirteenth day of hospitalization. (C) Regression of airspace and ground glass opacities with fibrous changes in the right upper and middle lobe and left upper lobe at the twenty-third day of hospitalization.
In this case, after MSC administration we observed a reduction in leukocyte count, D-dimer levels, and CRP-levels, all of which are prognostic factors for COVID-19 severity (20-23) (Table 2, Figure 2). The D-dimer reduction was particularly impressive. A recent multicentric study demonstrated that elevated D-dimer levels (2.025 mg/L cutoff) correlate with poor prognosis (24). Despite the increased D-dimer levels, pulmonary angiography showed no signs of pulmonary embolism. However, the first MSC dose was applied a day after the convalescent plasma application, which can confound the interpretation of the observed effect. Nevertheless, the progressive clinical deterioration and the ARDS development were not stopped. The third MSC dose was applied on the sixteenth day of hospitalization and coincided with the radiographic regression of ARDS. The following day, the patient was extubated and switched to high-flow oxygen. These observations lead us to believe that MSC therapy may show a visible effect in a 24-hour period after administration, but the treatment is potentially only effective in the setting of acute inflammatory conditions driven by cytokine storm, such as ARDS. However, we cannot confirm this observation because the required biomarkers were unavailable for analysis. This case did, however, demonstrate that compassionate MSC application was well tolerated after three treatment rounds, as no adverse events were observed that could be directly attributed to the procedure. Similar results were demonstrated in a case series by Hashemian et al, who reported a positive clinical effect (improved Sa\textsubscript{O}2 and dyspnea) in 5 out of 11 patients who received prenatal (umbilical cord- and placenta-derived) MSC infusion in a two- to three-day period (25). The authors also reported a decrease in proinflammatory parameters (TNF-alpha, IL-6, IL-8, CRP) on the fifth day of treatment (24 hours after the third dose of MSCs). These parameters were not monitored in our patient, so we are unable to compare the results of the two studies (25). A prolonged hospital stay in COVID-19 patients can be complicated by hospital-acquired bacterial superinfections (26,27). The ex-

Figure 2. Inflammatory parameters by the day of hospitalization. (A) C-reactive protein (CRP); (B) D-dimers. The red lines represent the days when mesenchymal stem cells were applied.
act incidence of superinfections in Croatian hospitals has not been established, but they affect both the patient’s prognosis and length of hospital stay (28). Our patient had a superinfection with S. aureus and A. baumannii confirmed in the bronchial aspirate upon bronchoscopy on day 12. We effectively treated the patient with colistin, fosfomycin, and linezolid. The second bacterial infection was found in blood cultures (gram-negative bacilli) on day 20, after the patient was already extubated and clinically improving. Ceftazidime/avibactam therapy was successful, and the patient’s leukocyte count decreased to physiological levels in two days. These findings indicate the need for special attention when it comes to bacterial superinfections in COVID-19 patients, as they already have a weakened immune system. In our experience, the isolated specimens did not differ between COVID-19 and non-COVID-19 patients.

The main study limitations were the ability to obtain only the laboratory parameters used in daily clinical practice, which prevented us from analyzing the levels of cytokines driving the inflammatory response. Second, the use of convalescent plasma, remdesivir, and immunosuppressive drugs before MSC application prevent us from drawing independent conclusions on MSC efficacy. We were unable to exclude these factors, as MSC therapy has never before been used for COVID-19 treatment in Croatia, and the standard treatment protocols include the mentioned medications. Other limitations include a short follow-up and our inability to draw definite conclusions since the study was limited only to a single case. The observed effect of MSC in combination with readily used therapeutic measures should be further studied in larger patient cohorts and in centers able to perform more sophisticated laboratory analyses. However, since there is no currently available treatment for severe COVID-19, we propose MSC to be considered in patients who do not respond to commonly used therapeutic options.

Acknowledgment MSC treatment was made possible by the cooperation of Educell Ltd, St. Catherine Specialty Hospital, and the International Society for Applied Biological Sciences (ISABS).

Funding The convalescent plasma project was supported by the Croatian Science Foundation (grant IP-CORONA-04-2053 to BH) and by the European Regional Development Fund, grant number KK.01.1.1.01.0006, "Strengthening the Capacity of CeriVac for Research in Virus Immunology and Vaccinology.

Ethical approval The patient gave written informed consent for the publication of data and images.

Declaration of authorship DP and SSS conceived and designed the study; DP, SSS, MS, LG, AB, MF, II, DMK, BH, and AH acquired the data; DP, SSS, II, VMa, and VMo analyzed and interpreted the data; DP, MS, IJ, BH, AH, VMa, and VMo drafted the manuscript; DP, SSS, MS, LG, AB, MF, II, DMK, VMa, and VMo critically revised the manuscript for important intellectual content; all authors gave approval of the version to be submitted; all authors agree to be accountable for all aspects of the work.

Competing interests AH, BH, and IJ received grants by the Croatian Science Foundation (IP-CORONA-04-2053) and by the European Regional Development Fund, grant number KK.01.1.1.01.0006, “Strengthening the Capacity of CeriVac for Research in Virus Immunology and Vaccinology. All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

References
1. Coperchini F, Chiavoti L, Cocco L, Magri F, Rotondi M. The cytokines storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020;53:25-32. Medline:32446778 doi:10.1016/j.cytogfr.2020.05.003
2. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507-13. Medline:32007143 doi:10.1016/S0140-6736(20)30211-7
3. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11:216-28. Medline:32257537 doi:10.14336/AD.2020.0228
4. Rnjak D, Ravič S, Šola A-M, Halassy B, Šemnički J, Šuperba M, et al. COVID-19 convalescent plasma as long-term therapy in immunodeficient patients? Transfus Clin Biol. 2021. Medline:33901641 doi:10.1016/j.trci.2021.04.004
5. Garraud O, Heshmati F, Pozzetto B, Lefrere F, Girot R, Saillol A, et al. Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow. Transfus Clin Biol. 2016;23:39-44. Medline:26775794 doi:10.1016/j.trci.2015.12.003
6. Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ. 2020;26:368:m1256. Medline:32217555 doi:10.1136/bmj.m1256
7. Brave H, MacLoughlin R. State of the art review of cell therapy in the treatment of lung disease, and the potential for aerosol delivery. Int J Mol Sci. 2020;21:6435. Medline:32899381 doi:10.3390/ijms21176435
8. Primorac D, Molnar V, Rod E, Jeleč Ž, Čukelj F, Matišić V, et al. Knee osteoarthritis: A review of pathogenesis and state-of-the-art non-operative therapeutic considerations. Genes (Basel). 2020;11:854. Medline:32722615 doi:10.3390/genes11080854
9. Hudetz D, Boric I, Rod E, Jeleč Ž, Radič A, Vrdoljak T, et al. The effect of intra-articular administration of autologous microfragmented fat tissue with adipose-derived mesenchymal stem cells on proteoglycan synthesis in patients with knee osteoarthritis. Genes (Basel). 2017;8:270. doi:10.3390/genes8100270
10. Hudetz D, Jeleč Ž, Rod E, Borić I, Pliečko M, Primorac D. The future...
of cartilage repair. In: Personalized medicine in healthcare systems: legal, medical and economic implications. Bodiroga-Vukobrat N, Rukavina D, Pavletic K, Sander GG, editors. Cham: Springer Nature Switzerland; 2019. p. 375-411.

11 Durand N, Mallea J, Zubair AC. Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure. NPJ Regen Med. 2020;5:17. Medline:33580031 doi:10.1038/s41536-020-00105-z

12 Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee JW, et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells. 2010;28:2229-38. Medline:20945332 doi:10.1002/stem.544

13 Fischer U, Marting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 2009;18:683-92. Medline:19099374 doi:10.1089/scd.2008.0253

14 de Witte SFH, Luk F, Sierra Parraga JM, Gargesha M, Merino A, Koreevaar SS, et al. Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytes cells. Stem Cells. 2018;36:602-15. Medline:29341339 doi:10.1002/stem.2779

15 Abumaree MH, Al Junah MA, Khalibon B, Jawdat D, Al Khaldi A, Abomaray FM, et al. Human placental mesenchymal stem cells (pMSCs) play a role as immune suppressive cells by shifting macrophage differentiation from inflammatory M1 to anti-inflammatory M2 macrophages. Stem Cell Res Rev. 2013;9:620-41. Medline:23812784 doi:10.1007/s12015-013-9455-2

16 Khatri M, Richardson LA, Meulia T. Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model. Stem Cell Res Ther. 2018;9:17. Medline:29378639 doi:10.1186/s13287-018-0774-8

17 National Library of Medicine (U.S.) Available from. https://www.clinicaltrials.gov/ct2/results?recrs=&cond=Covid19&term=mesenchymal+stem+cells&cntry=&state=&city=&dist

18 Sanchez-Guijo F, Garcia-Arranz M, Lopez-Parras M, Monedero P, Mata-Martinez C, Santos A, et al. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study. ECLinicalMedicine. 2020;25:100454. Medline:32838232 doi:10.1016/j.eclinm.2020.100454

19 Qu W, Wang Z, Hare JM, Bu G, Mallea JM, Pascual JM, et al. Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome. Stem Cells Transl Med. 2020;9:1007-22. Medline:32472653 doi:10.1002/sctm.20-0146

20 Carubbi F, Salvati L, Alunno A, Maggi F, Borghi E, Mariani R, et al. Ferritin is associated with the severity of lung involvement but not with worse prognosis in patients with COVID-19: data from two Italian COVID-19 units. Sci Rep. 2021;11:4863. Medline:33649408 doi:10.1038/s41598-021-83831-8

21 Huang I, Pranata R, Lim MA, Dehadain A, Alisjahbana B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis. 2021;14:1753466620937175. Medline:32615866

22 Singh K, Mittal S, Gollapudi S, Butzmann A, Kumar J, Ohgami RS. A meta-analysis of SARS-CoV-2 patients identifies the combinatorial significance of D-dimer, C-reactive protein, lymphocyte, and neutrophil values as a predictor of disease severity. Int J Lab Hematol. 2020. Medline:33010111 doi:10.1111/ijlh.13354

23 Mueller AA, Tamura T, Crowley CP, DeGrado Jr, Haider H, Jezmir JL, et al. Inflammatory biomarker trends predict respiratory decline in COVID-19 patients. Cell Rep Med. 2020;1:100144. Medline:33163981 doi:10.1016/j.xcrm.2020.100144

24 He X, Yao F, Chen J, Wang Y, Fang X, Lin X, et al. The poor prognosis and influencing factors of high D-dimer levels for COVID-19 patients. Sci Rep. 2021;11:1830. Medline:33469072 doi:10.1038/s41598-021-81300-w

25 Hashemian SR, Alannejad R, Zarrabi M, Soleimani M, Vasough H, Mosseini SE, et al. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Stem Cell Res Ther. 2021;12:91. Medline:33414427 doi:10.1186/s13287-021-02165-4

26 Garcia-Vidal C, Sanjuan G, Moreno-Garcia E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021;27:83-8. Medline:32745596 doi:10.1016/j.cmi.2020.07.041

27 Falcone M, Tiseo G, Giordano C, Leonardi L, Menichini M, Vecchione A, et al. Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study. J Antimicrob Chemother. 2021;76:1078-84. Medline:3374002 doi:10.1093/jac/dkaa530

28 Chaaeri A, Mifsud B, Bahloul M, Mahjoubi F, Chitra K, Turki O, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiology, clinical characteristics, and prognosis factors. Int J Infect Dis. 2013;17:1225-8. Medline:24094525 doi:10.1016/j.ijid.2013.07.014